ArticleKidney international reports2026
Scoping Review of Polygenic Risk Scores in Kidney-Related Traits.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Large-scale genome-wide association studies (GWAS) have identified numerous loci associated with various diseases and traits, enabling the development of polygenic risk scores (PRS) and genetic risk scores (GRS) that capture cumulative effects of variants. Although these scores have been applied in nephrology, no review has systematically evaluated their implementation or performance. This review aimed to summarize the current landscape of PRS and GRS related to kidney traits and diseases. Methods: In April 2025, we searched PubMed, Embase, Scopus, and Web of Science for peer-reviewed articles and preprints following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis extension for Scoping Review guidelines. Studies were included if they developed or evaluated PRS and GRS for kidney-related traits. Data on study characteristics, score construction, and performance metrics were extracted. Results: Of the 1947 records identified, 104 met the inclusion criteria, encompassing 129 unique scores or evaluations. The most frequently studied traits were chronic kidney disease (CKD, Conclusion: Current evidence suggests that the clinical utility of PRS and GRS in nephrology depends on the context. Improved diversity, phenotype definition, and methodological standardization are essential for enhancing translational potential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.